Common CMC Issues in Type II DMFs and How to Avoid Them

  Рет қаралды 2,949

U.S. Food and Drug Administration

U.S. Food and Drug Administration

Күн бұрын

FDA discusses common quality issues in DMF submissions and briefly discusses resolution strategies and point to consider in order to enhance DMF submissions.
Presenter:
Wei Liu, Division of Lifecycle API
Learn more at: www.fda.gov/dr...
-------------------- 
FDA CDER’s Small Business and Industry Assistance (SBIA) educates and provides assistance in understanding the regulatory aspects of human drug products & clinical research.  

Upcoming Training - www.fda.gov/cd...
SBIA Listserv - public.govdeli...
SBIA 2021 Playlist - • 2021 CDER Small Busine...
SBIA LinkedIn: / cder-small-business-an...
SBIA Training Resources - www.fda.gov/cd...
Twitter - / fda_drug_info
Email - CDERSBIA@fda.hhs.gov  
Phone - (301) 796-6707 I (866) 405-5367

Пікірлер
Drug Substance Postapproval Changes Guidance: Determination of Impurity Profile Equivalence
23:25
U.S. Food and Drug Administration
Рет қаралды 4,3 М.
CMC - NDA requirements and Common Pitfalls of BLAs (14of15) REdI - May 29-30, 2019
1:10:48
U.S. Food and Drug Administration
Рет қаралды 10 М.
Chain Game Strong ⛓️
00:21
Anwar Jibawi
Рет қаралды 41 МЛН
Гениальное изобретение из обычного стаканчика!
00:31
Лютая физика | Олимпиадная физика
Рет қаралды 4,8 МЛН
We Attempted The Impossible 😱
00:54
Topper Guild
Рет қаралды 56 МЛН
Common CMC (Quality) Issues and How to Avoid Them Part I (12of16) Generic Drugs Forum
57:58
U.S. Food and Drug Administration
Рет қаралды 7 М.
ICH M7(R1) - Chemistry and Manufacturing Control (CMC) Perspective on Hazard Assessment
20:33
U.S. Food and Drug Administration
Рет қаралды 7 М.
Chemistry and Manufacturing Requirements for Early Clinical Development: What’s in there? Prove it.
1:02:19
Regulatory Considerations for Impurity Qualification: ICH Q3A/Q3C/Q3D, RLD & MDD
28:12
U.S. Food and Drug Administration
Рет қаралды 10 М.
Electronic Common Technical Document (eCTD) and Study Data (7of15) RedI - May 29-30, 2019
55:56
U.S. Food and Drug Administration
Рет қаралды 12 М.
CMC Considerations for CAR T Cell Product Development
29:42
U.S. Food and Drug Administration
Рет қаралды 12 М.
FDA Clinical Investigator Training Course (CITC) 2024 - Day One - Session Two
1:42:25
U.S. Food and Drug Administration
Рет қаралды 686
FDA Clinical Investigator Training Course (CITC) 2024 - Day One - Session One
2:14:51
U.S. Food and Drug Administration
Рет қаралды 517
Questions and Panel Discussion - Post-approval CMC and Manufacturing - REdI 2020
30:07
U.S. Food and Drug Administration
Рет қаралды 1,9 М.
FDA Clinical Investigator Training Course (CITC) 2024 - Day Two - Session One
1:51:03
U.S. Food and Drug Administration
Рет қаралды 329